The Rapidly Evolving Treatment Landscape for CLL and Focused Updates for Managed Care

This activity was originally broadcast live as a satellite symposium held in conjunction with the 2022 AMCP Annual Meeting.

Program Description

Clinical staging and prognostic indicators have an important role in predicting prognosis and guiding treatment decisions for patients with chronic lymphocytic leukemia (CLL). While traditional first-line therapies for CLL have been a combination of chemotherapy and anti-CD20 monoclonal antibodies, current guidelines including oral BTK and BCL-2 inhibitors have changed the treatment landscape. However, there are significant challenges of therapy with these agents for patients, including adverse effects, drug resistance, and economic burden, all of which lead to discontinuation and nonadherence for patients. Managed care pharmacists are well positioned to address these obstacles by utilizing clinical safety and efficacy data of BTK and BCL-2 inhibitors to establish evidence-based protocols for their use in the treatment and management of patients with CLL. Considerations for managed care professionals to mitigate adverse effects of therapy and improve medication adherence will also be discussed.

Target Audience: Managed care pharmacists and oncology pharmacists

Type of Activity: Application
Release date: April 22, 2022
Expiration date: April 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the clinical data supporting current therapies and the emerging data of combination therapies for CLL.
• Interpret the association between BTK selectivity and the occurrence of toxicities and steps to mitigate these adverse effects.
• Investigate the data on treatment options that may improve the economic burden of CLL treatment while optimizing clinical outcomes.

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-197-H01-P. The activity is available for CE credit through April 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amanda N. Seddon, PharmD, BCPS, BCOP, and Jerilyn Arneson, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff— Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Chloe Taccetta; and Brianna Winters have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms